Scientists pinpoint ideal opioid dose for smoother airway insertion
NCT ID NCT06289829
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study aims to find the best dose of remifentanil, a fast-acting opioid, for inserting a laryngeal mask airway (a type of breathing tube) during anesthesia with remimazolam. Researchers will test different doses in 60 adults having short elective surgeries, adjusting the dose based on whether insertion is successful. The goal is to improve patient comfort and safety by reducing movement or breathing problems during the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- remifentanil
- What this could lead to
- If successful, this could help anesthesiologists use the right dose of remifentanil for smoother and safer airway device insertion.
- What could go wrong
- This is a small, early-phase study with only 60 patients, so results may not apply to everyone. The optimal dose found may still cause side effects or fail in some cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 19 years or older and less than 65 years * ASA physical status classification I, II, or III * Scheduled for elective surgery lasting within 3 hours under general anesthesia using a laryngeal mask Exclusion Criteria: * Refusal to participate in the study * Unable to read the consent form or comprehend the research process (e.g., illiteracy, foreign nationality, cognitive impairment) * Anatomic structures that are anticipated to cause difficulty in mask ventilation * History of difficulty in airway management * Upper respiratory infections or respiratory conditions (e.g., asthma, pneumonia) * Risk of aspiration (e.g., gastroesophageal reflux) * Allergies to anesthesia-related drugs, such as benzodiazepines or opioid analgesics * Impaired liver or kidney function * Pregnant or breastfeeding patients * Obesity (body mass index \> 30 kg/m2) * History of drug or alcohol abuse.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adult, laryngeal masks, remimazolam, remifentanil are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
Seoul, South Korea